(Updated with final closing prices)
Shares of companies that make heart devices mostly traded higher Tuesday, after Boston Scientific (BSX) reported successful trial results for one of its products, which analysts said could lead to better sales of other items.
Boston Scientific said its device designed to re-coordinate the pumping of the right and left ventricles, called a cardiac resynchronization therapy defibrillator, reduced death and the need for hospitalization in heart failure patients. Boston Scientific said its device was more effective than traditional implantable cardioverter defibrillators.
The devices deliver electric shocks to the heart to restore a normal rhythm. Use of implantable heart devices has slumped in recent years because of product recalls and safety concerns."There is no question that the penetration of CRT-D devices will increase," said Jefferies analyst Peter Bye, because the trial data could lead to expanded health insurance and Medicare coverage for implants. However, he said, it's not clear how many more patients will be considered good candidates for the implants. Boston Scientific shares rose 27 cents, or 2.9%, to close at $9.51. Shares of St. Jude Medical (STJ), a company Bye singled out as a beneficiary of improved sales, added $1.01, or 2.6%, to $40.55. Elsewhere, shares of Abbott Laboratories (ABT) gained 15 cents to $46.86 and Medtronic's (MDT) stock gained 18 cents, to $33.37. Shares of Johnson & Johnson (JNJ) slipped 48 cents to $55.01.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV